Esperion (ESPR) Plummets 54% Over Milestone Payment Row

This article was originally published on Nasdaq

The share price of Esperion Therapeutics ESPR lost 54.3% on Mar 16 after management reported a disagreement with one of its partners over certain milestone payments.

Responses